<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-424
Date of Submission: 2025-04-13

This report was submitted by a Pharmacist from Garcia, Gordon and Green Medical Center concerning patient ANON-PX-1438. The subject is a 53-year-old other with a significant medical history including hypertension, seasonal allergies, anxiety, osteoarthritis. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Atorvastatin administered via the Oral route at a dosage of 270mg, initiated on 2025-01-22 for Hypercholesterolemia and discontinued on 2025-03-31.

On approximately 2025-03-29, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Dizziness, Vomiting. The Dizziness was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed professor and advised job. The current patient status regarding this symptom is 'Fatal'. The Vomiting was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 2 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Negative dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. 

Reporter's Narrative Summary: Like third spend participant fight build head. Continue hair best treat bag.</data>
report_id: ADR-2025-424
report_date: '2025-04-13'
patient_details:
  patient_id: ANON-PX-1438
  gender: Other
  relevant_history:
  - hypertension
  - seasonal allergies
  - anxiety
  - osteoarthritis
  age_at_reaction: 53
suspected_drugs:
- drug_name: Atorvastatin
  dosage: 270mg
  route_of_administration: Oral
  start_date: '2025-01-22'
  indication_for_use: Hypercholesterolemia
  end_date: '2025-03-31'
adverse_reactions:
- symptom_name: Dizziness
  onset_date: '2025-03-29'
  severity: Moderate
  outcome: Fatal
  intervention_required: true
  intervention_details: Prescribed professor and advised job.
- symptom_name: Vomiting
  onset_date: '2025-03-29'
  severity: Mild
  outcome: Recovered
  intervention_required: false
causality_assessment:
  assessment_conclusion: Possible
  dechallenge_rechallenge: Negative dechallenge
  naranjo_score: 2
reporting_facility: Garcia, Gordon and Green Medical Center
reporter_type: Pharmacist
notes: Like third spend participant fight build head. Continue hair best treat bag.
